NASDAQ:MBRX

Moleculin Biotech Stock Forecast, Price & News

$3.11
+0.16 (+5.42 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.90
$3.11
50-Day Range
$2.70
$3.57
52-Week Range
$2.70
$8.78
Volume154,739 shs
Average Volume1.30 million shs
Market Capitalization$88.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.93
30 days | 90 days | 365 days | Advanced Chart
Receive MBRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.


Moleculin Biotech logo

About Moleculin Biotech

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML); and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.93 out of 5 stars

Medical Sector

1244th out of 1,351 stocks

Pharmaceutical Preparations Industry

611th out of 664 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions

What stocks does MarketBeat like better than Moleculin Biotech?

Wall Street analysts have given Moleculin Biotech a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Moleculin Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Moleculin Biotech?

Moleculin Biotech saw a drop in short interest in July. As of July 30th, there was short interest totaling 771,800 shares, a drop of 18.7% from the July 15th total of 949,900 shares. Based on an average daily trading volume, of 266,500 shares, the days-to-cover ratio is currently 2.9 days. Currently, 2.9% of the company's stock are sold short.
View Moleculin Biotech's Short Interest
.

When is Moleculin Biotech's next earnings date?

Moleculin Biotech is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Moleculin Biotech
.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) released its quarterly earnings results on Tuesday, August, 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04.
View Moleculin Biotech's earnings history
.

How has Moleculin Biotech's stock been impacted by Coronavirus?

Moleculin Biotech's stock was trading at $3.0306 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MBRX stock has increased by 2.6% and is now trading at $3.11.
View which stocks have been most impacted by COVID-19
.

When did Moleculin Biotech's stock split? How did Moleculin Biotech's stock split work?

Moleculin Biotech shares reverse split on Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of Moleculin Biotech stock prior to the reverse split would have 17 shares after the split.

Who are Moleculin Biotech's key executives?

Moleculin Biotech's management team includes the following people:
  • Walter V. Klemp, Chairman, President & Chief Executive Officer
  • Jonathan P. Foster, Chief Financial Officer & Executive Vice President
  • Robert Shepard, Chief Medical Officer-Annamycin
  • Donald H. Picker, Chief Science Officer
  • Sandra Leta Silberman, Chief Medical Officer-New Products

Who are some of Moleculin Biotech's key competitors?

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

Who are Moleculin Biotech's major shareholders?

Moleculin Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.68%), Geode Capital Management LLC (0.84%), State Street Corp (0.21%), Citadel Advisors LLC (0.13%), XTX Topco Ltd (0.12%) and GSA Capital Partners LLP (0.11%).
View institutional ownership trends for Moleculin Biotech
.

Which institutional investors are buying Moleculin Biotech stock?

MBRX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Geode Capital Management LLC, State Street Corp, XTX Topco Ltd, GSA Capital Partners LLP, Goldman Sachs Group Inc., Virtu Financial LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Moleculin Biotech
or or view top insider-buying stocks.

How do I buy shares of Moleculin Biotech?

Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $3.11.

How much money does Moleculin Biotech make?

Moleculin Biotech has a market capitalization of $88.80 million. The company earns $-17,350,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Moleculin Biotech have?

Moleculin Biotech employs 13 workers across the globe.

What is Moleculin Biotech's official website?

The official website for Moleculin Biotech is www.moleculin.com.

Where are Moleculin Biotech's headquarters?

Moleculin Biotech is headquartered at 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The company can be reached via phone at (713) 300-5160 or via email at [email protected]


This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.